Amprion poses ‘significant execution risk’

Moody’s believes Amprion’s €3.3bn, 10-year capex programme ‘will not only burden the company’s financial performance, but also test its technical and managerial capabilities’. A consortium of institutional investors led by Commerz Real spent €1.3bn recently acquiring 74.9% of Amprion.